Survival and recurrence.

<p>Abbreviations: RFS, relapse free survival.</p><p>Survival and recurrence.</p

Local and overall recurrence rates in patients with low-risk locally advanced rectal cancer.

<p>(A) Cumulative local recurrence rate. (B) Cumulative overall recurrence rate.</p

Local control of patients with number of lymph nodes retrieved≤12 (dashed line), and number of lymph nodes retrieved>12 (solid line).

<p>Local control of patients with number of lymph nodes retrieved≤12 (dashed line), and number of lymph nodes retrieved>12 (solid line).</p

Details of patients with local recurrence.

<p>Abbreviations: CEA, serum carcinoembryonic antigen; RFS, relapse free survival.</p><p>Details of patients with local recurrence.</p

ROC curve to determine the IBL cutoff volume.

<p>ROC curve to determine the IBL cutoff volume.</p

Kaplan–Meier curves for overall survival (a) and recurrence free survival (b) after CRLM resection for the entire patient cohort.

<p>The median OS for all patients was 73.2 months, and the proportion of patients alive at 3 and 5 years was 65% and 53%, respectively. The median RFS period was 30.7 months.</p

The survival curves for patients in different time durations (A) and with different tumor locations (B).

<p>The survival curves for patients in different time durations (A) and with different tumor locations (B).</p

Additional file 1 of The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study

Additional file 1: Fig S1. Flow of study